FY2024 EPS Estimates for Curaleaf Cut by Atb Cap Markets

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) – Stock analysts at Atb Cap Markets reduced their FY2024 EPS estimates for Curaleaf in a research note issued on Thursday, November 7th. Atb Cap Markets analyst F. Gomes now forecasts that the company will earn ($0.24) per share for the year, down from their prior forecast of ($0.21). The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Atb Cap Markets also issued estimates for Curaleaf’s Q4 2024 earnings at ($0.04) EPS and FY2025 earnings at ($0.14) EPS.

A number of other analysts have also issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $6.25 price target on shares of Curaleaf in a research note on Thursday, August 8th. Cormark downgraded Curaleaf from a “moderate buy” rating to a “hold” rating in a research report on Thursday, November 7th.

Curaleaf Stock Down 22.1 %

Shares of OTCMKTS:CURLF opened at $1.66 on Monday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.09 and a quick ratio of 0.50. The firm has a market capitalization of $1.08 billion, a PE ratio of -5.72 and a beta of 0.86. The firm’s 50-day moving average is $2.95 and its two-hundred day moving average is $3.77. Curaleaf has a 1 year low of $1.64 and a 1 year high of $6.40.

Curaleaf Company Profile

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.